Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

NCT01790659 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

399

Enrollment

FED

Sponsor class

Conditions

Cutaneous Leishmaniasis

Interventions

DRUG: WR 279,396
DRUG: Paromomycin

Sponsor

U.S. Army Medical Research and Development Command